Overview
BAIYUNSHAN PH (874)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People’s Republic of China and interna...
- Open
- 12.600
- High
- 12.630
- Low
- 12.560
- Prev. Close
- 12.580
- Volume
- 738.00K
- Turnover
- 9.29M
- Avg Price
- 12.586
- Bid/Ask Ratio
- -75.00%
- Amplitude
- 0.56%
- 52wk High
- 19.537
- Volume Ratio
- 0.79
- Turnover Ratio
- 0.34%
- 52wk Low
- 12.520
- HK Mkt Cap
- 2.77B
- Market CapHKD
- 20.48B
- P/ETTM
- 8.12
- P/EDynamic
- 5.29
- P/EStatic
- --
- EPSTTM
- 1.55
- EPSDynamic
- 2.38
- EPSStatic
- --
- BVPS
- 27.97
- P/B
- 0.45
- HK Shares
- 219.90M
- Dividend YieldTTM
- 6.85%
- DividendTTM
- 0.863
- Shares
- 1.63B
- Min lot size
- 2,000
- Currency
- HKD
BAIYUNSHAN PH Analyst Rating
View moreForecast & Rating
Nov 4, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Hong Kong trading saw the stock rise to HKD 12.63 in morning session (10:09 HKT), but afternoon weakness prevailed, with the high capped at HKD 12.60 and closing at HKD 12.60—flat versus the prior close of HKD 12.58. This intraday sell-off pattern underscores market concerns about fundamentals. Q3 results revealed net profit of HKD 462.88 million, down 46.66% year-over-year, despite operating revenue growing 8.19%, as margin erosion weighed on sentiment. Year-to-date, the stock has tumbled 30.58% from HKD 18.15 to current levels, now sitting just 0.64% above the 52-week low of HKD 12.52, signaling accumulation near multi-month lows. Valuation has compressed to P/E 8.12 and P/B 0.45—historic lows. Recent initiatives including pursuit of a strategic investor for its operations and subsidiary equity raises have done little to lift sentiment, suggesting the market awaits operational turnaround evidence rather than financial restructuring.
- Nov, 13
Guangzhou Baiyunshan Pharmaceutical shares closed slightly lower at HKD 12.58 on November 13, down 0.87% from the prior close of HKD 12.69, bringing the stock to within 0.48% of the 52-week low of HKD 12.52 established on October 29—a fresh benchmark touched just two weeks prior. Year-to-date performance has deteriorated markedly by 30.69% from the year's opening price of HKD 18.15, and the shares now trade 38.33% below the 52-week high of HKD 20.4 set a year ago. Profitability pressures remain acute: Q3 earnings per share plunged 46.57% year-over-year to HKD 0.2851, while net profit contracted 46.66% to approximately RMB 462 million despite reasonable revenue growth of 8.19% to RMB 23.38 billion; net profit margin compressed to just 1.98%. Recent corporate initiatives—including an Extraordinary General Meeting and board approval of subsidiary share placement programs totaling up to RMB 6 billion—point to structural adjustments underway. Notably, current valuations are deeply discounted with PE of 8.11 and PB of 0.45, while offering an elevated dividend yield of 6.86%.
- Nov, 12
Baiyunshan Pharmaceutical closed down around 1% to 12.69 HKD today, driven by intensifying profit deterioration. Q3 net income plummeted 46.66% year-over-year to HKD 463 million while earnings per share crashed 46.57% to HKD 0.2851, despite revenue growth of 8.19% to HKD 23.38 billion—net margin compressed to just 1.98%. The stock has tumbled 30.08% year-to-date and now trades just above its 52-week low of 12.52 HKD set on October 29, down 37.79% from the 20.40 HKD peak in November last year. Shares are trading below both the 20-day moving average of 12.993 HKD and 60-day moving average of 13.361 HKD. Valuation has compressed significantly: PE ratio stands at 8.18x with PB at 0.45x and dividend yield at 6.80%. The board recently approved a subsidiary capital placement of up to RMB 6 billion, signaling management confidence, though the profitability recovery trajectory remains uncertain.
- Nov, 11
Baiyunshan declined 0.62% to HKD 12.82 today in quiet trading, with intraday trading ranging from morning high of 12.97 to afternoon lows around 12.82-12.85. Year-to-date the stock has fallen 29.37%, trading 37.16% below its 52-week high of HKD 20.4 and approaching its 52-week low of HKD 12.52, marking a sharp drawdown from historical levels. The board's recent approval of a subsidiary financing plan of up to RMB 6 billion signals company capital requirements. On the earnings front, Q3 revenue grew 8.19% year-over-year to HKD 23.38 billion, yet net income declined 46.66% to HKD 463 million, showing some moderation from Q2's 52.68% YoY drop; however, net margin further compressed to 1.98%. Trading at historically depressed valuations (PE 8.27, PB 0.46), the stock has failed to attract significant buyers, suggesting persistent doubts about near-term profit recovery.
- Nov, 9
Baiyunshan's stock fell 1.3% today, closing at HKD 12.88 from a gap-up opening of HKD 13.30 at 9:30 AM, as the market continues to digest the third quarter's profit plunge. Net income in Q3 tumbled 46.66% year-over-year to HKD 463 million, following an even steeper 52.68% decline in Q2, despite revenue growing 8.19% to HKD 23.38 billion, signaling severe deterioration in profitability with Q3 net margin shrinking to just 1.98%. From a price perspective, the stock has slumped 36.86% from its 52-week high of HKD 20.4 and is hovering near the 52-week low of HKD 12.52, marking a 29.04% decline year-to-date. The stock has broken below both its 20-day moving average of 13.068 and 60-day moving average of 13.476, reflecting persistent bearish momentum. However, valuation metrics remain deeply depressed with a PE ratio of only 8.3 and PB ratio of 0.46, suggesting the market has already priced in a bleak forward outlook.
News
Tip Ranks · Baiyunshan Seeks Approval for GP Corp. Strategic Investor Plan
PUBT · Guangzhou Baiyunshan Pharmaceutical Announces Extraordinary General Meeting
Tip Ranks · Guangzhou Baiyunshan Sets H-Share Register Closure Ahead of EGM
PUBT · Guangzhou Baiyunshan Board Approves Subsidiary Share Placement of Up to RMB 6 Billion
